TN2013000389A1 - BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 - Google Patents

BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2

Info

Publication number: TN2013000389A1
Authority: TN; Tunisia
Prior art keywords: dll4; ang2; binding; binding molecules; bispecific
Prior art date: 2011-04-01

Application number

TNP2013000389A

Other languages

English (en)

Inventor

Andreas Gschwind

Rene Georg Ott

Joachim Boucneau

Marie-Ange Buyse

Erik Depla

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2013-09-26

Publication date

2015-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000389(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-26 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-01-20 Publication of TN2013000389A1 publication Critical patent/TN2013000389A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Microbiology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2013000389A 2011-04-01 2013-09-26 BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 TN2013000389A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11160920		2011-04-01
PCT/EP2012/055897 WO2012131076A1 (fr)	2011-04-01	2012-03-30	Molécules de liaison bispécifiques se liant à dll4 et ang2

Publications (1)

Publication Number	Publication Date
TN2013000389A1 true TN2013000389A1 (en)	2015-01-20

Family

ID=44314095

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000389A TN2013000389A1 (en)	2011-04-01	2013-09-26	BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2

Country Status (23)

Country	Link
US (1)	US20130078247A1 (fr)
EP (1)	EP2694545B1 (fr)
JP (1)	JP2014511682A (fr)
KR (1)	KR20140016345A (fr)
CN (2)	CN103596977B (fr)
AP (1)	AP2013007086A0 (fr)
AR (1)	AR085919A1 (fr)
AU (1)	AU2012234218A1 (fr)
BR (1)	BR112013025294A2 (fr)
CA (1)	CA2827809A1 (fr)
CL (1)	CL2013002622A1 (fr)
CO (1)	CO6801638A2 (fr)
EA (1)	EA201301109A1 (fr)
EC (1)	ECSP13012996A (fr)
MA (1)	MA35233B1 (fr)
MX (1)	MX337115B (fr)
PE (1)	PE20141157A1 (fr)
PH (1)	PH12013502031A1 (fr)
SG (1)	SG193557A1 (fr)
TN (1)	TN2013000389A1 (fr)
TW (2)	TWI535735B (fr)
UY (1)	UY33997A (fr)
WO (1)	WO2012131076A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
HRP20190817T1 (hr) *	2012-03-30	2019-06-28	Boehringer Ingelheim International Gmbh	Ang2-vezujuće molekule
CA2883807A1 (fr) *	2012-09-28	2014-04-03	Boehringer Ingelheim International Gmbh	Combinaisons pharmaceutiques comprenant des liants doubles angiopoietine-2/dll4 et des agents anti-vegf-r
MX2015003894A (es) *	2012-09-28	2015-07-17	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf.
EP3143138B1 (fr)	2014-05-13	2022-03-23	BioAtla, Inc.	Protéines biologiques conditionnellement actives
CN107540747B (zh) *	2017-08-09	2020-01-24	苏州大学附属儿童医院	抗人dll4单克隆抗体6f12
CN110950967B (zh) *	2019-12-13	2022-05-13	山东民康生物科技有限公司	抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
US20240425575A1 (en) *	2021-09-10	2024-12-26	Soter Biopharma Pte. Ltd	Anti-ang2 antibody, preparation method therefor, and application thereof
CN116444675B (zh) *	2023-05-11	2023-12-22	亲和(武汉)生命科技有限责任公司	一种Pfu DNA聚合酶纳米抗体及其制备方法和应用
WO2025111816A1 (fr) *	2023-11-28	2025-06-05	Eluminex Biosciences Limited	Protéines de fusion multispécifiques ciblant des facteurs angiogéniques, inflammatoires et/ou fibrotiques

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0656946T4 (da)	1992-08-21	2010-07-26	Univ Bruxelles	Immunoglobuliner uden lette kæder
EP0739981A1 (fr)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
WO2001079271A1 (fr)	2000-04-12	2001-10-25	Principia Pharmaceutical Corporation	Proteines fusionnees a l'albumine
CN101684158A (zh)	2001-01-17	2010-03-31	特鲁比昂药品公司	结合域-免疫球蛋白融合蛋白
AU2002319402B2 (en)	2001-06-28	2008-09-11	Domantis Limited	Dual-specific ligand and its use
EP1463752A4 (fr)	2001-12-21	2005-07-13	Human Genome Sciences Inc	Proteines de fusion d'albumine
CA2505326A1 (fr)	2002-11-08	2004-05-21	Ablynx N.V.	Procede d'administration de polypeptides therapeutiques et polypeptides associes
AU2003286003B2 (en)	2002-11-08	2011-05-26	Ablynx N.V.	Stabilized single domain antibodies
EP1578842B1 (fr)	2002-12-31	2009-10-07	Nektar Therapeutics Al, Corporation	Polymeres a terminaison maleimide hydrolytiquement stables
CN1845938B (zh)	2003-06-30	2010-05-26	杜门蒂斯有限公司	多肽
EP2251357A1 (fr)	2003-11-07	2010-11-17	Ablynx N.V.	Anticorps VHH de domaine unique de camélidés dirigés contre le récepteur du facteur de croissance épidermique et utilisations correspondantes
US20050284249A1 (en)	2004-06-29	2005-12-29	Arnone David F	Worm type gear mover assembly
KR20070084170A (ko)	2004-10-13	2007-08-24	아블린쓰 엔.브이.	알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
HUE045710T2 (hu)	2005-05-18	2020-01-28	Ablynx Nv	Javított, alfa tumor nekrózis faktor elleni nanobodies
DK1962895T3 (da) *	2005-12-16	2013-03-04	Regeneron Pharma	TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
MX2008015532A (es) *	2006-06-06	2008-12-18	Genentech Inc	Composiciones y metodos para la modulacion del desarrollo vascular.
UA94464C2 (ru) *	2006-06-06	2011-05-10	Дженентек, Инк.	Выделенное антитело к dll4 и его применение
CL2007001623A1 (es) *	2006-06-06	2008-01-18	Genentech Inc	Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo.
CA2666599A1 (fr)	2006-08-18	2008-02-21	Ablynx N.V.	Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
US20100113339A1 (en) *	2006-09-08	2010-05-06	Ablynx N. V.	Serum albumin binding proteins with long half-lives
RU2448979C2 (ru) *	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
CA2681974C (fr) *	2007-03-29	2019-12-31	Genmab A/S	Anticorps bispecifiques et procedes de production de ceux-ci
WO2009095489A2 (fr)	2008-02-01	2009-08-06	Ablynx N.V.	Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
AU2009221106A1 (en)	2008-03-05	2009-09-11	Ablynx Nv	Novel antigen binding dimer-complexes, methods of making and uses thereof
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
AU2009294415B2 (en) *	2008-09-19	2015-09-24	Medimmune Llc	Antibodies directed to DLL4 and uses thereof
US8268314B2 (en) *	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) *	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32920A (es) *	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es) *	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moléculas de unión a dll-4
AR080794A1 (es) *	2010-03-26	2012-05-09	Hoffmann La Roche	Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2

2012
- 2012-03-29 US US13/433,354 patent/US20130078247A1/en not_active Abandoned
- 2012-03-30 TW TW101111544A patent/TWI535735B/zh not_active IP Right Cessation
- 2012-03-30 TW TW101111526A patent/TWI551612B/zh active
- 2012-03-30 CN CN201280026737.XA patent/CN103596977B/zh not_active Expired - Fee Related
- 2012-03-30 AU AU2012234218A patent/AU2012234218A1/en not_active Abandoned
- 2012-03-30 AR ARP120101129A patent/AR085919A1/es unknown
- 2012-03-30 EA EA201301109A patent/EA201301109A1/ru unknown
- 2012-03-30 JP JP2014501664A patent/JP2014511682A/ja not_active Ceased
- 2012-03-30 BR BR112013025294A patent/BR112013025294A2/pt not_active IP Right Cessation
- 2012-03-30 MX MX2013011032A patent/MX337115B/es active IP Right Grant
- 2012-03-30 CN CN201610374703.XA patent/CN106046167A/zh active Pending
- 2012-03-30 EP EP12711200.1A patent/EP2694545B1/fr not_active Not-in-force
- 2012-03-30 UY UY0001033997A patent/UY33997A/es unknown
- 2012-03-30 WO PCT/EP2012/055897 patent/WO2012131076A1/fr not_active Ceased
- 2012-03-30 AP AP2013007086A patent/AP2013007086A0/xx unknown
- 2012-03-30 KR KR1020137028119A patent/KR20140016345A/ko not_active Withdrawn
- 2012-03-30 CA CA2827809A patent/CA2827809A1/fr not_active Abandoned
- 2012-03-30 SG SG2013070792A patent/SG193557A1/en unknown
- 2012-03-30 PE PE2013002157A patent/PE20141157A1/es not_active Application Discontinuation
2013
- 2013-09-12 CL CL2013002622A patent/CL2013002622A1/es unknown
- 2013-09-26 TN TNP2013000389A patent/TN2013000389A1/fr unknown
- 2013-09-27 MA MA36275A patent/MA35233B1/fr unknown
- 2013-09-27 CO CO13230710A patent/CO6801638A2/es unknown
- 2013-09-30 PH PH12013502031A patent/PH12013502031A1/en unknown
- 2013-10-25 EC ECSP13012996 patent/ECSP13012996A/es unknown

Also Published As

Publication number	Publication date
CN103596977B (zh)	2016-07-06
CL2013002622A1 (es)	2014-02-14
AP2013007086A0 (en)	2013-08-31
MA35233B1 (fr)	2014-07-03
TWI535735B (zh)	2016-06-01
NZ614243A (en)	2015-04-24
EA201301109A1 (ru)	2014-08-29
EP2694545A1 (fr)	2014-02-12
MX337115B (es)	2016-02-12
PE20141157A1 (es)	2014-09-24
TWI551612B (zh)	2016-10-01
CA2827809A1 (fr)	2012-10-04
AU2012234218A1 (en)	2013-09-05
CN103596977A (zh)	2014-02-19
MX2013011032A (es)	2013-12-06
CN106046167A (zh)	2016-10-26
TW201302789A (zh)	2013-01-16
BR112013025294A2 (pt)	2017-06-13
SG193557A1 (en)	2013-11-29
CO6801638A2 (es)	2013-11-29
UY33997A (es)	2012-09-28
EP2694545B1 (fr)	2016-08-24
ECSP13012996A (es)	2013-12-31
PH12013502031A1 (en)	2013-12-16
WO2012131076A1 (fr)	2012-10-04
KR20140016345A (ko)	2014-02-07
AR085919A1 (es)	2013-11-06
JP2014511682A (ja)	2014-05-19
TW201302797A (zh)	2013-01-16
US20130078247A1 (en)	2013-03-28

Publication	Publication Date	Title
TN2013000390A1 (en)	2015-01-20	Bispecific binding molecules binding to vegf and ang2
TN2013000389A1 (en)	2015-01-20	BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
TN2012000144A1 (en)	2013-09-19	Dll4-binding molecules
IN2014DN06904A (fr)	2015-05-15
PH12013500410B1 (en)	2022-02-11	Vegf-binding molecules
WO2014004549A3 (fr)	2014-03-13	Protéines de liaison anti-mésothéline
MY193112A (en)	2022-09-26	Anti pd-1 and anti-lag3 antibodies for cancer treatment
TN2012000145A1 (en)	2013-09-19	Bispecific binding molecules for anti-angiogenesis therapy
PH12014502527A1 (en)	2015-01-12	St2 antigen binding proteins
HK1209434A1 (en)	2016-04-01	Agents for treatment of claudin expressing cancer diseases
PH12012501838A1 (en)	2013-02-04	Aptamers to ã-ngf and their use in treating ã-ngf mediated diseases and disorders
WO2012135671A3 (fr)	2012-12-13	Anticorps monoclonaux contre inhibiteur de la voie du facteur tissulaire (tfpi)